natgillin/translations-raw huggingface dataset:
• As cases of tuberculosis have been reported in patients treated with Humira, your doctor will check you for signs and symptoms of tuberculosis before starting Humira. 
• Ker so bili pri bolnikih, zdravljenih z zdravilom Humira, opisani primeri tuberkuloze, vas bo zdravnik pred začetkom zdravljenja z zdravilom Humira preiskal glede znakov in simptomov tuberkuloze.
The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind, parallel − group study in 171 children (4-17 years old) with polyarticular JIA. 
Varnost in učinkovitost zdravila Humira so ocenili v multicentrični randomizirani dvojno slepi študiji vzporednih skupin pri 171 otrocih (starih od 4 do 17 let) s poliartikularnim juvenilnim idiopatskim artritisom.
Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of Humira/MTX was administered every other week up to 10 years. 
Po zaključenih prvih 52 tednih so 457 bolnikov vključili v odprto nadaljevalno fazo, med katero so dobivali 40 mg zdravilo Humira/MTX vsak drugi teden v obdobju do 10 let.
Methotrexate should be continued during treatment with Humira. 
Med zdravljenjem z zdravilom Humira je treba še naprej uporabljati metotreksat.
In an analysis in which all patients who dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and 55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks). 
Opravljena je bila analiza, v kateri so vse bolnike, ki so izpadli iz študije zaradi neželenih učinkov ali nezadostne učinkovitosti, ali jim je bil povečan odmerek, obravnavali kot neodzivne; pri teh bolnikih sta bila po dodatnih 108 tednih odprtega zdravljenja (skupaj 160 tednov) delež odziva
• elevated bilirubin measurement (liver blood test). 
• povišane vrednosti bilirubina (test jetrne krvi).
In the open-label extension, improvement in the signs and symptoms was maintained with Humira therapy through Week 156. 
Pri podaljšanih odprtih študijah se je pri zdravljenju z zdravilom Humira izboljšanje znakov in simptomov ohranjalo do 156. tedna.
RA studies VI and VII each evaluated 60 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old. 
Študiji revmatoidnega artritisa VI in VII sta vsaka ocenili po 60 bolnikov z zmernim do hudim revmatoidnim artritisom, starih ≥ 18 let.
• leukaemia (cancer affecting the blood and bone marrow) 
• levkemija (rak, ki prizadene kri in kostni mozeg)
Placebo/ MTX 
placebo/ MTXa
95% confidence intervals for the differences in change scores between methotrexate and Humira. 
Ocena ZSŠd ametotreksat b95 % intervali zaupanja za razlike v spremembi ocen med metotreksatom in zdravilom Humira cna podlagi analize rangov dzožitev sklepne špranje
Week 26 Placebo-Controlled 
teden Kontrolirana s placebom
In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) treated with 0.8 mg/kg adalimumab monotherapy. 
Pri pediatričnih bolnikih s psoriazo so bila protitelesa proti adalimumabu odkrita pri 5/38 oseb (13 %), ki so bile zdravljene z monoterapijo adalimumaba 0,8 mg/kg.
5) Injecting Humira 
5) Injiciranje zdravila Humira
Ask your doctor or pharmacist how to throw away medicines you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Table 15 Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II 
Odziv učinkovitosti v s placebom kontroliranem obdobju študije nr-axSpA II
Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). 
Zdravilo Humira je v kombinaciji z metotreksatom indicirano za zdravljenje aktivnega poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2. leta starosti, ki se ne odzovejo ustrezno na eno ali več imunomodulirajočih antirevmatičnih zdravil.
The safety and efficacy of Humira were assessed in two randomized, double-blind placebo controlled studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). 
Varnost in učinkovitost zdravila Humira so ocenili v dveh randomiziranih dvojno slepih, s placebom kontroliranih študijah pri bolnikih z ne-radiografskim aksialnim spondiloartritisom (nr-axSpA).
Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. 
Pri uporabi zdravila Humira so se nekateri od hepatospleničnih limfomov celic T pojavili pri mladih odraslih bolnikih, ki so se sočasno zdravili z azatioprinom ali 6-merkaptopurinom, ki se uporabljata pri vnetni bolezni črevesa.
It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Humira. 
Priporočljivo je, da med zdravljenjem z zdravilom Humira bolnik vsak dan uporablja topikalno antiseptično čistilno sredstvo za čiščenje lezij HS.
• Humira is a liquid that is clear and colourless. 
• Zdravilo Humira je bistra in brezbarvna tekočina.
Do not rub the injection site. 
Injekcijskega mesta NE DRGNITE.
Humira Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis 
Odmerjanje zdravila Humira pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom
Skin cancer excluding melanoma (including basal cell carcinoma and squamous cell carcinoma), 
pogosti karcinom kože, ki ne vključuje malignega melanoma (vključno z bazalnoceličnim karcinomom in ploščatoceličnim karcinomom),
Tell your doctor immediately if your child experiences symptoms like changes in vision, weakness in arms or legs or numbness or tingling in any part of the body. 
Zdravniku takoj povejte, če se pri vašem otroku pojavijo simptomi, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu telesa.
Time to Treatment Failure At or After Week 6 in Study UV I Primary analysis (ITT) Placebo Adalimumab 110 60 (54.5) 5.6 Time to Treatment Failure At or After Week 2 in Study UV II Primary analysis (ITT) Placebo Adalimumab 115 45 (39.1) NE Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted as event. 
Primarna analiza (ITT) Placebo Adalimumab 115 45 (39,1) NEc Opomba: Neuspeh zdravljenja v ali po 6. tednu (študija UV I) ali v ali po 2. tednu (študija UV II) je bil štet kot dogodek.
When combining controlled portions of these trials and ongoing and completed open label extension studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 patient-years of therapy, the observed rate of malignancies, other than lymphoma and nonmelanoma skin cancers is approximately 8.5 per 1,000 patient years. 
Če vzamemo skupaj kontrolirane dele teh preskušanj in potekajoče in zaključene odprte nadaljevalne študije z medianim trajanjem približno 3,3 leta s 6427 bolniki in prek 26439 bolnikov-let zdravljenja, je ugotovljeni delež malignomov (razen limfoma in nemelanomskih kožnih rakov) približno 8,5 na 1000 bolnikov-let.
Patients who maintained PASI 75 response at Week 33 and were originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg Humira every other week or placebo for an additional 19 weeks. 
Bolnike, ki so imeli 33. teden ohranjen odziv PASI ≥ 75 in so bili v obdobju A randomizirani na aktivno terapijo, so med obdobjem C ponovno randomizirali tako, da so dodatnih 19 tednov dobivali 40 mg zdravila Humira vsak drugi teden ali placebo.
Humira 40 mg every other week N = 70 
Humira 40 mg vsak drugi teden N = 70
This study evaluated the efficacy of Humira 40 mg every other week/methotrexate combination therapy, Humira 40 mg every other week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression of joint damage in rheumatoid arthritis for 104 weeks. 
Ta študija je ocenila učinkovitost treh shem (kombinirano zdravljenje z zdravilom Humira 40 mg vsak drugi teden/metotreksatom, monoterapija z zdravilom Humira 40 mg vsak drugi teden in monoterapija z metotreksat) za zmanjšanje znakov in simptomov ter hitrosti napredovanja sklepne okvare pri revmatoidnem artritisu v obdobju 104 tednov.
• signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding, 
• znaki in simptomi, ki nakazujejo bolezni krvi, npr. dolgotrajno zvišana telesna temperatura, modrice, krvavitve, bledica
In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of patients treated with adalimumab. 
Pri bolnikih z artritisom, povezanim z entezitisom so protitelesa proti adalimumabu ugotovili pri 10,9 % (5/46) bolnikov, ki so dobivali adalimumab.
• Ankylosing spondylitis 
• ankilozirajočega spondilitisa
• angioedema (localized swelling of the skin) 
• angioedem (lokalizirano otekanje kože)
Of 207 patients, 81 patients continued on Humira 40 mg every other week for 10 years. 
Od 207 bolnikov jih je 81 nadaljevalo zdravljenje z zdravilom Humira 40 mg vsak drugi teden še 10 let.
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively). 
Približno dvakratni delež bolnikov v skupini, ki je prejemala placebo, je v primerjevi s tistimi, ki so bili v skupini z zdravilom Humira, je v prvih 12. tednih študije HS-I in HSII, doživelo poslabšanje abscesov (23,0 % v primerjavi z 11,4 %, v tem zaporedju) in fistul z izcedkom (30,0 % v primerjavi s 13,9 %, v tem zaporedju).
The Humira pre-filled syringe is available in a pack containing 1 pre-filled syringe for patient use with 1 alcohol pad. 
Napolnjena injekcijska brizga zdravila Humira je na voljo v pakiranju, ki vsebuje 1 napolnjeno injekcijsko brizgo z 1 alkoholnim zložencem.
Hold the pre-filled pen with the grey cap (labelled ‘1') pointing up. 
Napolnjeni injekcijski peresnik držite tako, da bo sivi pokrovček (označen z '1') obrnjen navzgor.
The usual dose for adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis and for patients with psoriatic arthritis is 40 mg adalimumab given every other week as a single dose. 
Običajni odmerek za odrasle z revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za ankilozirajoči spondilitis in za bolnike s psoriatičnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku.
Of 207 patients who were randomised to Humira 40 mg every other week, 114 patients continued on Humira 40 mg every other week for 5 years. 
Od 207 bolnikov, ki so bili randomizirani na zdravilo Humira 40 mg vsak drugi teden, jih je 114 nadaljevalo zdravljenje z zdravilom Humira 40 mg vsak drugi teden še 5 let.
The usual dose of Humira is 20 mg every other week with methotrexate. 
Običajni odmerek zdravila Humira je 20 mg vsak drugi teden z metotreksatom.
UNIQUE INDENTIFIER - 2D BARCODE 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs). 
Aksialni spondiloartritis brez radiografskega dokaza za AS Zdravilo Humira je indicirano za zdravljenje odraslih s hudim aksialnim spondiloartritisom brez radiografskega dokaza za AS, toda z objektivnimi znaki vnetja s povišanimi CRP in/ali MRI, ki so nezadostno reagirali na ali ne prenašajo nesteroidnih protivnetnih zdravil.
• leukemia (cancer affecting the blood and bone marrow); 
• levkemija (rak, ki prizadene kri in kostni mozeg);
Psoriatic arthritis is an inflammatory disease of the joints that is usually associated with psoriasis. 
Psoriatični artritis je vnetna bolezen sklepov, ki je običajno povezana s kožno luskavico.
Figure 1: Kaplan-Meier Curves Summarizing Time to Flare in Study nr-axSpA II 
Slika 1: Kaplan-Meier-jeve krivulje povzemajo čas do ponovnega zagona bolezni v študiji nr-axSpA II
The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients. 
Delež (95 % interval zaupanja) nemelanomskih kožnih rakov je bil 8,8 (6,0; 13,0) na 1000 bolnikovlet med bolniki, ki so dobivali zdravilo Humira, in 3,2 (1,3; 7,6) na 1000 bolnikov-let med kontrolnimi bolniki.
In patients with psoriatic arthritis, anti-adalimumab antibodies were identified in 38/376 subjects (10%) treated with adalimumab. 
Med bolniki s psoriatičnim artritisom so protitelesa proti adalimumabu ugotovili pri 38/376 (10 %) tistih, ki so dobivali adalimumab.
Rheumatoid arthritis Age or body weight 
Revmatoidni artritis Starost ali telesna masa
Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. 
Luskavica v plakih je bolezen kože, pri kateri nastajajo rdeče, kosmičaste, krastave lise na koži, pokrite s srebrnimi luskami.
• Your child's belly (abdomen) at least 5 cm from his/her belly button (navel) 
• na trebuhu vašega otroka; najmanj 5 cm oddaljeno od popka
• Using your thumb or a piece of gauze, apply pressure over the injection site for 10 seconds. 
• S palcem ali koščkom gaze 10 sekund pritiskajte na injekcijsko mesto.
Do not remove the needle cover until just before injection. 
Pokrovček igle odstranite šele tik pred injiciranjem.
Pulmonary fibrosis 
pljučna fibroza1)
Tell your doctor immediately if you experience symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body. 
Zdravniku takoj povejte, če se pri vas pojavijo simptomi, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu telesa.
In subjects treated with Humira with no radiographic progression from baseline to Week 48 (n=102), 84% continued to show no radiographic progression through 144 weeks of treatment. 
Pri 84 % preiskovancev, ki so dobivali zdravilo Humira in od izhodišča do 48. tedna niso imeli rentgenografsko vidnega napredovanja (n = 102), se takšno napredovanje tudi do 144. tedna zdravljenja ni pojavilo.
• intestinal infections (including gastroenteritis) 
• črevesne okužbe (vključno z gastroenteritisom)
• cancer that affects the lymph system 
• rak, ki zajame limfni sistem
If the remaining volume is less than the prescribed dose volume, DO NOT use the syringe and contact your healthcare provider. 
Če je preostala količina manjša od količine predpisanega odmerka, brizge, NE
Patients with at least a partial response to Humira 40 mg weekly after 12 weeks of treatment. 
36. teden a Bolniki z vsaj delnim odzivom na odmerek 40 mg Humira po 12. tednih zdravljenja.
The posology of Humira in these patients has been determined from pharmacokinetic modelling and simulation (see section 5.2). 
Kliničnih študij z zdravilom Humira pri mladostnikih s HS ni. Odmerjanje zdravila Humira pri teh bolnikih je bilo določeno na podlagi farmakokinetičnega modeliranja in simulacije (glejte poglavje 5.2).
In patients with polyarticular juvenile idiopathic arthritis who were 2 to < 4 years old or aged 4 and above weighing <15 kg, anti-adalimumab antibodies were identified in 7% (1/15) of patients, and the one patient was receiving concomitant methotrexate. 
Med bolniki s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 2 do < 4 let ali 4 leta in več in so tehtali <15 kg, so protitelesa proti adalimumabu ugotovili pri 7 % (1/15) bolnikov, en bolnik je sočasno prejemal metotreksat.
>32 weeks 
> 32 tednov 20 tednov
Humira is administered every other week via subcutaneous injection. 
Zdravilo Humira se odmerja vsak drugi teden v obliki subkutane injekcije.
• Do not recycle or throw the pre-filled syringe in the household waste 
• Uporabljene napolnjene injekcijske brizge ne reciklirajte ali zavrzite med gospodinjske odpadke.
At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical remission (DAS28 (CRP) < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving Humira monotherapy. 
Po 52. tednih je klinično remisijo (DAS28 (CRP)< 2,6) doseglo 42,9 % bolnikov, ki so dobivali kombinirano terapijo z zdravilom Humira/metotreksatom, 20,6 % bolnikov, ki so dobivali metotreksat v monoterapiji, in 23,4 % bolnikov, ki so dobivali zdravilo Humira v monoterapiji.
Fever, bruising, bleeding or looking pale 
modrice, krvavitve, bledica
• acid reflux disease 
• bolezen refluksa kisline
• People with more serious rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting lymphoma (a cancer that affects the lymph system) and leukaemia (a cancer that affects the blood and bone marrow). 
• Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom (rak, ki prizadene limfatični sistem) in levkemijo (rak, ki prizadene kri in kostni mozeg).
With automatic needle guard. 
S ščitnikom za iglo.
2-sided P value from log rank test. NE = not estimable. 
2-stranska vrednost p testa log-rank.
• severe rash, hives or other signs of allergic reaction 
• hud izpuščaj, koprivnico ali druge znake alergijske reakcije
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at Week 52 were 9.5±5.6g/ml for the Standard Dose group and 3.5±2.2 g/ml for the Low Dose group. 
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile povprečne najmanjše koncentracije adalimumaba v 52. tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
• hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal) 
• jetrnovranični limfom celic T (redka oblika krvnega raka, ki je pogosto smrtna)
Place the white end of the pre-filled pen at a right angle (90 degrees) to the skin, so that you can see the window. 
Namestite beli konec napolnjenega injekcijskega peresnika pravokotno (90 stopinj) na kožo,
c Inactive Disease Partial Flare Assessment of SpondyloArthritis international Society Baseline is defined as open label baseline when patients have active disease. 
Delni zagon boleznid a ocena spondiloartritičnega mednarodnega združenja (Assessment of Spondyloarthritis International Society b izhodišče je določeno kot izhodišče odprte faze, ko imajo bolniki aktivno bolezen c ocena bolezenske aktivnosti ankilozirajočega spondilitisa (Ankylosing Spondylitis Disease
Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. 
Zdravilo Humira je indicirano za zdravljenje zmerne do hude kronične psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.
This risk may increase if your child has problems with his/her lungs. 
Tveganje je lahko večje, če ima vaš otrok okvarjeno delovanje pljuč.
Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. 
Zdravilo Humira so raziskali pri bolnikih z revmatoidnim artritisom, poliartikularnim juvenilnim idiopatskim artritisom in psoriatičnim artritisom, ki so zdravilo Humira jemali v monoterapiji, kot pri tistih, ki so jo jemali hkrati z metotreksatom.
• gallbladder inflammation, gallbladder stones 
• vnetje žolčnika, žolčni kamni
• Using a piece of gauze, apply pressure over the injection site for 10 seconds. 
• S koščkom gaze 10 sekund pritiskajte na injekcijsko mesto.
Your doctor may recommend temporary discontinuation. 
Vaš zdravnik bo morda priporočil začasno prenehanje uporabe zdravila
The safety profile for patients with uveitis treated with Humira every other week was consistent with the known safety profile of Humira. 
Varnostni profil za bolnike z uveitisom, ki so bili vsak drugi teden zdravljeni z zdravilom Humira, je v skladu z znanim varnostnim profilom zdravila Humira.
• a bump or open sore that doesn't heal 
• bula ali odprta rana, ki se ne zaceli
• Keep pushing the pre-filled pen down firmly against the injection site until the injection is complete. 
• Trdno potiskajte napolnjen injekcijski peresnik proti mestu injiciranja, dokler injiciranje ni končano.
During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 Humira treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated patients). 
V kontroliranih delih preskušanj, ki podpirajo vlogo za pridobitev dovoljenja za promet zdravila Humira pri odraslih, ki so trajala vsaj 12 tednov, pri bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS, psoriatičnim artritisom, psoriazo, hidradenitis suppurativa, Crohnovo boleznijo, ulceroznim kolitisom in uveitisom so malignome (razen limfoma in nemelanomskega kožnega raka) opažali z deležem (95 % interval zaupanja) 6,8 (4,4; 10,5) na 1000 bolnikov-let med 5291 bolniki, ki so dobivali zdravilo Humira, in 6,3 (3,4; 11,8) na 1000 bolnikov-let med 3444 kontrolnimi bolniki (pri prvih je zdravljenje mediano trajalo 4,0 meseca in pri drugih 3,8 meseca).
- infections, including tuberculosis - cancer - nervous system problems - vaccinations 
- okužbe, vključno s tuberkulozo, - rak,
Myocardial infarction arrhythmia, congestive heart failure 
pogosti tahikardija občasni miokardni infarkt1) aritmija kongestivno srčno popuščanje redki zastoj srca
• lung diseases causing shortness of breath (including inflammation) 
• pljučna bolezen, ki povzroči kratko sapo (vključno z vnetjem)
Do not put either of the caps back on the pre-filled pen. 
Ne enega ne drugega pokrovčka ne natikajte nazaj na napolnjeni injekcijski peresnik.
It is important to tell your doctor if your child has had or has a serious heart condition (see “Warnings and precautions”). 
Pomembno je, da zdravniku poveste, če je vaš otrok imel ali ima resno bolezen srca (glejte "Opozorila in previdnostni ukrepi").
In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, 
V kontroliranih in odprtih študijah pri odraslih in otrocih z zdravilom Humira so poročali o resnih okužbah (vključno s smrtno nevarnimi okužbami, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana ali zunajpljučna histoplazmoza, blastomikoza, kokcidioidomikoza, pnevmocistoza, kandidaza,
Each pack contains 1, 2, 4 or 6 pre-filled syringes for patient use with 1, 2, 4 or 6 alcohol pads, respectively. 
Eno pakiranje vsebuje 1, 2, 4 oz. 6 napolnjenih injekcijskih brizg za bolnikovo uporabo z 1, 2, 4 oz. 6 alkoholnimi zloženci.